Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort

Published 2019 View Full Article

Authors

Keywords

Coronary heart disease, Cardiovascular risk, LDL cholesterol, Proprotein convertase subtilisin/kexin type 9 , (, PCSK9), Cost-effectiveness, Quality Adjusted Life Years (QALYs), Incremental cost-effectiveness ratio (ICER)

Journal

VASCULAR PHARMACOLOGY

Volume -, Issue -, Pages 106566

Publisher

Elsevier BV

Online

2019-06-14

DOI

10.1016/j.vph.2019.106566

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.